Veracyte Statistics
Total Valuation
Veracyte has a market cap or net worth of $1.63 billion. The enterprise value is $1.43 billion.
| Market Cap | 1.63B |
| Enterprise Value | 1.43B |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, after market close.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Veracyte has 76.45 million shares outstanding. The number of shares has increased by 3.58% in one year.
| Shares Outstanding | 76.45M |
| Shares Change (YoY) | +3.58% |
| Shares Change (QoQ) | +2.25% |
| Owned by Insiders (%) | 0.82% |
| Owned by Institutions (%) | 105.34% |
| Float | 76.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.33 |
| Forward PS | 3.87 |
| PB Ratio | 1.45 |
| P/FCF Ratio | 61.74 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 54.28 |
Financial Position
The company has a current ratio of 5.00, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.00 |
| Quick Ratio | 4.43 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.53 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -6.30% and return on invested capital (ROIC) is -7.06%.
| Return on Equity (ROE) | -6.30% |
| Return on Assets (ROA) | -5.90% |
| Return on Capital (ROIC) | -7.06% |
| Revenue Per Employee | $460,703 |
| Profits Per Employee | -$83,653 |
| Employee Count | 815 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 7.47 |
Taxes
| Income Tax | -2.25M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.69% in the last 52 weeks. The beta is 1.70, so Veracyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.70 |
| 52-Week Price Change | -14.69% |
| 50-Day Moving Average | 21.29 |
| 200-Day Moving Average | 23.16 |
| Relative Strength Index (RSI) | 46.18 |
| Average Volume (20 Days) | 854,937 |
Short Selling Information
The latest short interest is 4.52 million, so 5.91% of the outstanding shares have been sold short.
| Short Interest | 4.52M |
| Short Previous Month | 4.44M |
| Short % of Shares Out | 5.91% |
| Short % of Float | 5.94% |
| Short Ratio (days to cover) | 6.74 |
Income Statement
In the last 12 months, Veracyte had revenue of $375.47 million and -$68.18 million in losses. Loss per share was -$0.93.
| Revenue | 375.47M |
| Gross Profit | 257.34M |
| Operating Income | -79.95M |
| Pretax Income | -70.43M |
| Net Income | -68.18M |
| EBITDA | -39.93M |
| EBIT | -70.43M |
| Loss Per Share | -$0.93 |
Balance Sheet
The company has $210.27 million in cash and $14.04 million in debt, giving a net cash position of $196.23 million or $2.57 per share.
| Cash & Cash Equivalents | 210.27M |
| Total Debt | 14.04M |
| Net Cash | 196.23M |
| Net Cash Per Share | $2.57 |
| Equity (Book Value) | 1.12B |
| Book Value Per Share | 14.63 |
| Working Capital | 232.37M |
Cash Flow
In the last 12 months, operating cash flow was $37.43 million and capital expenditures -$11.10 million, giving a free cash flow of $26.33 million.
| Operating Cash Flow | 37.43M |
| Capital Expenditures | -11.10M |
| Free Cash Flow | 26.33M |
| FCF Per Share | $0.35 |
Margins
Gross margin is 68.54%, with operating and profit margins of -21.29% and -18.16%.
| Gross Margin | 68.54% |
| Operating Margin | -21.29% |
| Pretax Margin | -18.76% |
| Profit Margin | -18.16% |
| EBITDA Margin | -10.63% |
| EBIT Margin | -18.76% |
| FCF Margin | 7.01% |
Dividends & Yields
Veracyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.58% |
| Shareholder Yield | -3.58% |
| Earnings Yield | -4.19% |
| FCF Yield | 1.62% |
Analyst Forecast
The average price target for Veracyte is $27.50, which is 29.35% higher than the current price. The consensus rating is "Buy".
| Price Target | $27.50 |
| Price Target Difference | 29.35% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Veracyte has an Altman Z-Score of 11.78 and a Piotroski F-Score of 6.
| Altman Z-Score | 11.78 |
| Piotroski F-Score | 6 |